首页 > 最新文献

Current Allergy and Asthma Reports最新文献

英文 中文
The Potential of Human Monoclonal IgE Antibodies to Establish Biological Potency and Stability of Allergen Extracts. 人类单克隆 IgE 抗体在确定过敏原提取物的生物效力和稳定性方面的潜力。
IF 5.4 2区 医学 Q1 ALLERGY Pub Date : 2024-09-01 Epub Date: 2024-07-24 DOI: 10.1007/s11882-024-01168-4
Ronald L Rabin

Purpose of review: Allergenic extracts are often standardized to control for potency, either by measuring concentrations of major allergens or "overall allergenicity" by competition for IgE in pooled sera from highly allergic subjects with a reference extract. Recent developments present an opportunity to use human mAb cloned from highly allergic subjects to define potency of allergenic extracts.

Recent findings: Two recent developments present an opportunity for revising potency measurements of allergen extracts: cloning allergen specific IgE from allergic subjects and extensive epitope mapping of major allergenic proteins. Because human IgE mAb recognize biologically relevant epitopes, they present a novel opportunity to determine the potencies of allergenic extracts and may contribute to the science base for allergen standardization.

审查目的:过敏原提取物通常通过测量主要过敏原的浓度或通过高度过敏受试者与参考提取物的集合血清中 IgE 的竞争来测量 "整体过敏性",从而对其进行标准化,以控制其效力。最近的发展为使用从高度过敏受试者身上克隆的人类 mAb 来确定过敏原提取物的效力提供了机会:最近的两项进展为修订过敏原提取物的效力测量提供了机会:从过敏受试者中克隆过敏原特异性 IgE 以及对主要过敏原蛋白进行广泛的表位图谱绘制。由于人类 IgE mAb 能识别与生物相关的表位,因此它们为确定过敏原提取物的效价提供了一个新的机会,并可能为过敏原标准化的科学基础做出贡献。
{"title":"The Potential of Human Monoclonal IgE Antibodies to Establish Biological Potency and Stability of Allergen Extracts.","authors":"Ronald L Rabin","doi":"10.1007/s11882-024-01168-4","DOIUrl":"10.1007/s11882-024-01168-4","url":null,"abstract":"<p><strong>Purpose of review: </strong>Allergenic extracts are often standardized to control for potency, either by measuring concentrations of major allergens or \"overall allergenicity\" by competition for IgE in pooled sera from highly allergic subjects with a reference extract. Recent developments present an opportunity to use human mAb cloned from highly allergic subjects to define potency of allergenic extracts.</p><p><strong>Recent findings: </strong>Two recent developments present an opportunity for revising potency measurements of allergen extracts: cloning allergen specific IgE from allergic subjects and extensive epitope mapping of major allergenic proteins. Because human IgE mAb recognize biologically relevant epitopes, they present a novel opportunity to determine the potencies of allergenic extracts and may contribute to the science base for allergen standardization.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":" ","pages":"471-475"},"PeriodicalIF":5.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11364621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141753432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Buckwheat Allergy in Asia. 亚洲的荞麦过敏症。
IF 5.4 2区 医学 Q1 ALLERGY Pub Date : 2024-09-01 Epub Date: 2024-07-08 DOI: 10.1007/s11882-024-01166-6
Naoki Kajita, Koichi Yoshida

Purpose of review: Buckwheat (BW) allergy is a significant issue in Asia. This review delves into three types of BW allergy: immediate food allergy; food-dependent, exercise-induced anaphylaxis (FDEIA) as a subset of immediate food allergy; and food protein-induced enterocolitis syndrome (FPIES); by comparing data from Asian and non-Asian countries.

Recent findings: Most studies on BW have been published in Japan and Korea, and only a few studies on the topic have been done outside Asia. To date, seven components of common BW (Fagopyrum esculentum) and four components of Tartary BW (Fagopyrum tartaricum) have been implicated in BW allergy. Although BW-sIgE has limited utility for evaluating immediate BW allergy, Fag e 3-specific IgE, one of the components of common BW, and the skin prick test are diagnostically useful. The present review aims to shed light on the current state of knowledge, highlight research gaps, and suggest future directions in the management and understanding of BW allergy.

审查目的:荞麦(BW)过敏是亚洲的一个重要问题。本综述通过比较亚洲和非亚洲国家的数据,深入研究了三种类型的荞麦过敏:直接食物过敏;作为直接食物过敏子集的食物依赖性运动诱发过敏性休克(FDEIA);以及食物蛋白诱发小肠结肠炎综合征(FPIES):最近的研究结果:大多数有关 BW 的研究都是在日本和韩国发表的,只有少数亚洲以外的国家进行过相关研究。迄今为止,普通 BW(Fagopyrum esculentum)的七种成分和鞑靼 BW(Fagopyrum tartaricum)的四种成分与 BW 过敏有关。虽然 BW-sIgE 在评估直接 BW 过敏方面的作用有限,但普通 BW 成分之一的 Fag e 3 特异性 IgE 和皮肤点刺试验在诊断方面却很有用。本综述旨在阐明目前的知识状况,强调研究差距,并提出管理和了解 BW 过敏的未来方向。
{"title":"Buckwheat Allergy in Asia.","authors":"Naoki Kajita, Koichi Yoshida","doi":"10.1007/s11882-024-01166-6","DOIUrl":"10.1007/s11882-024-01166-6","url":null,"abstract":"<p><strong>Purpose of review: </strong>Buckwheat (BW) allergy is a significant issue in Asia. This review delves into three types of BW allergy: immediate food allergy; food-dependent, exercise-induced anaphylaxis (FDEIA) as a subset of immediate food allergy; and food protein-induced enterocolitis syndrome (FPIES); by comparing data from Asian and non-Asian countries.</p><p><strong>Recent findings: </strong>Most studies on BW have been published in Japan and Korea, and only a few studies on the topic have been done outside Asia. To date, seven components of common BW (Fagopyrum esculentum) and four components of Tartary BW (Fagopyrum tartaricum) have been implicated in BW allergy. Although BW-sIgE has limited utility for evaluating immediate BW allergy, Fag e 3-specific IgE, one of the components of common BW, and the skin prick test are diagnostically useful. The present review aims to shed light on the current state of knowledge, highlight research gaps, and suggest future directions in the management and understanding of BW allergy.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":" ","pages":"549-557"},"PeriodicalIF":5.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141556005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Diagnosis of Allergy to Lipid Transfer Proteins. 脂质转移蛋白过敏的诊断。
IF 5.4 2区 医学 Q1 ALLERGY Pub Date : 2024-09-01 Epub Date: 2024-07-11 DOI: 10.1007/s11882-024-01164-8
Bianca Olivieri, Isabel J Skypala

Purpose of review: To provide an update on the diagnosis of non-specific Lipid Transfer Protein (nsLTP) allergy.

Recent findings: More publications report the presence of nsLTP allergy in Northern European countries and nsLTP sensitisation in children. Individuals are more likely to have severe reactions if there is recognition of increasing numbers of LTP components. Diagnosis is problematic; not all those with nsLTP allergy will have a positive test to a peach extract containing Pru p 3, the peach nsLTP. Sensitisation to nsLTP is being reported in more countries, including to the nsLTP in Cannabis Sativa in North America. Meals containing multiple nsLTP foods are more likely to be involved in co-factor reactions. Component-resolved diagnostics are superior to skin prick tests, to determine sensitisation to the individual nsLTP allergens causing symptoms and, in the future, the Basophil Activation test may best discriminate between sensitization and clinical allergy.

综述的目的:提供有关非特异性脂质转移蛋白(nsLTP)过敏诊断的最新信息:更多出版物报道了北欧国家存在非特异性脂质转移蛋白过敏以及儿童对非特异性脂质转移蛋白过敏。如果认识到 LTP 成分的数量不断增加,则个体更有可能出现严重反应。诊断是个问题;并非所有对 nsLTP 过敏的人都会对含有 Pru p 3(桃子 nsLTP)的桃子提取物检测呈阳性。越来越多的国家报告了对 nsLTP 过敏的情况,包括北美对大麻中的 nsLTP 过敏。含有多种 nsLTP 食物的膳食更有可能涉及共因反应。成分分辨诊断法优于皮肤点刺试验,可确定对引起症状的单个 nsLTP 过敏原是否致敏,将来,嗜碱性粒细胞活化试验可能是区分致敏和临床过敏的最佳方法。
{"title":"The Diagnosis of Allergy to Lipid Transfer Proteins.","authors":"Bianca Olivieri, Isabel J Skypala","doi":"10.1007/s11882-024-01164-8","DOIUrl":"10.1007/s11882-024-01164-8","url":null,"abstract":"<p><strong>Purpose of review: </strong>To provide an update on the diagnosis of non-specific Lipid Transfer Protein (nsLTP) allergy.</p><p><strong>Recent findings: </strong>More publications report the presence of nsLTP allergy in Northern European countries and nsLTP sensitisation in children. Individuals are more likely to have severe reactions if there is recognition of increasing numbers of LTP components. Diagnosis is problematic; not all those with nsLTP allergy will have a positive test to a peach extract containing Pru p 3, the peach nsLTP. Sensitisation to nsLTP is being reported in more countries, including to the nsLTP in Cannabis Sativa in North America. Meals containing multiple nsLTP foods are more likely to be involved in co-factor reactions. Component-resolved diagnostics are superior to skin prick tests, to determine sensitisation to the individual nsLTP allergens causing symptoms and, in the future, the Basophil Activation test may best discriminate between sensitization and clinical allergy.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":" ","pages":"509-518"},"PeriodicalIF":5.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141581584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral Janus Kinase Inhibitors in Pediatric Atopic Dermatitis. 口服 Janus 激酶抑制剂治疗小儿特应性皮炎
IF 5.4 2区 医学 Q1 ALLERGY Pub Date : 2024-09-01 Epub Date: 2024-08-06 DOI: 10.1007/s11882-024-01167-5
Elsy M Navarrete-Rodríguez, Désirée Larenas-Linnemann, Helena Vidaurri de la Cruz, Jorge A Luna-Pech, Esther Guevara Sanginés

Purpose of review: To analyze the efficacy and safety of Janus kinase inhibitors (JAKi) in the treatment of pediatric AD.

Recent findings: Adolescents with moderate and severe atopic dermatitis (AD) need systemic therapies, as stated several recent practice guidelines. (JAKi) have shown their efficacy in the treatment of adult AD, however, there is a lack of information concerning efficacy and safety of their use in pediatric AD. We found that the JAKi's abrocitinib (ABRO), baricitinib (BARI), and upadacitinib (UPA), are all an effective treatment option with a very fast onset of action for adolescents with moderate-to-severe AD. BARI was not effective in children between 2 and 10 years with moderate-to-severe AD. Fortunately, major safety issues with JAKi in adolescents with AD have not been documented in the trials, so far, contrasting with the reports in adults with AD, where these events have very rarely occurred. There are some reports of herpes zoster (HZ) infection in adolescents on JAKi, but it is not a major safety concern. Acne is a relatively common AE with UPA in adolescents; however, it is responsive to standard treatment. This review will help the clinician to choose among the JAKi according to the needs and clinical features of patients with moderate and severe AD. In the following years, with the advent of new biologicals and JAKi, these therapies will fall into place in each phase of the evolution of patients with AD.

综述目的分析Janus激酶抑制剂(JAKi)治疗小儿特应性皮炎的疗效和安全性:最近的研究结果:正如最近几份实践指南所述,患有中度和重度特应性皮炎(AD)的青少年需要系统治疗。(JAKi)在治疗成人特应性皮炎方面已显示出疗效,但在儿童特应性皮炎的疗效和安全性方面却缺乏相关信息。我们发现,JAKi 的阿罗西替尼 (ABRO)、巴利替尼 (BARI) 和乌达替尼 (UPA) 都是治疗中重度 AD 青少年的有效药物,而且起效非常快。BARI对2至10岁患有中度至重度AD的儿童无效。幸运的是,迄今为止,JAKi在青少年AD患者中的重大安全性问题尚未在试验中记录在案,这与成人AD患者的报告形成了鲜明对比,后者极少发生此类事件。有一些关于青少年服用JAKi后感染带状疱疹(HZ)的报道,但这并不是一个主要的安全问题。痤疮是青少年服用 UPA 后比较常见的一种 AE;但它对标准治疗有一定的反应。本综述有助于临床医生根据中度和重度 AD 患者的需求和临床特征选择 JAKi。在接下来的几年中,随着新型生物制剂和 JAKi 的出现,这些疗法将在 AD 患者演变的各个阶段发挥作用。
{"title":"Oral Janus Kinase Inhibitors in Pediatric Atopic Dermatitis.","authors":"Elsy M Navarrete-Rodríguez, Désirée Larenas-Linnemann, Helena Vidaurri de la Cruz, Jorge A Luna-Pech, Esther Guevara Sanginés","doi":"10.1007/s11882-024-01167-5","DOIUrl":"10.1007/s11882-024-01167-5","url":null,"abstract":"<p><strong>Purpose of review: </strong>To analyze the efficacy and safety of Janus kinase inhibitors (JAKi) in the treatment of pediatric AD.</p><p><strong>Recent findings: </strong>Adolescents with moderate and severe atopic dermatitis (AD) need systemic therapies, as stated several recent practice guidelines. (JAKi) have shown their efficacy in the treatment of adult AD, however, there is a lack of information concerning efficacy and safety of their use in pediatric AD. We found that the JAKi's abrocitinib (ABRO), baricitinib (BARI), and upadacitinib (UPA), are all an effective treatment option with a very fast onset of action for adolescents with moderate-to-severe AD. BARI was not effective in children between 2 and 10 years with moderate-to-severe AD. Fortunately, major safety issues with JAKi in adolescents with AD have not been documented in the trials, so far, contrasting with the reports in adults with AD, where these events have very rarely occurred. There are some reports of herpes zoster (HZ) infection in adolescents on JAKi, but it is not a major safety concern. Acne is a relatively common AE with UPA in adolescents; however, it is responsive to standard treatment. This review will help the clinician to choose among the JAKi according to the needs and clinical features of patients with moderate and severe AD. In the following years, with the advent of new biologicals and JAKi, these therapies will fall into place in each phase of the evolution of patients with AD.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":" ","pages":"485-496"},"PeriodicalIF":5.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141894966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Food-Pollen Cross-Reactivity and its Molecular Diagnosis in China. 中国的食用花粉交叉反应及其分子诊断。
IF 5.4 2区 医学 Q1 ALLERGY Pub Date : 2024-09-01 Epub Date: 2024-07-08 DOI: 10.1007/s11882-024-01162-w
Lan Zhao, Tingting Ma, Xiaoyan Wang, Hongtian Wang, Yi Liu, Shandong Wu, Linglin Fu, Luud Gilissen, Ronald van Ree, Xueyan Wang, Zhongshan Gao

Purpose of review: Plant-derived foods are one of the most common causative sources of food allergy in China, with a significant relationship to pollinosis. This review aims to provide a comprehensive overview of this food-pollen allergy syndrome and its molecular allergen diagnosis to better understand the cross-reactive basis.

Recent findings: Food-pollen cross-reactivity has been mainly reported in Northern China, Artemisia pollen is the major related inhalant source, followed by tree pollen (Betula), while grass pollen plays a minor role. Pollen allergy is relatively low in Southern China, with allergies to grass pollen being more important than weed and tree pollens. Rosaceae fruits and legume seeds stand out as major related allergenic foods. Non-specific lipid transfer protein (nsLTP) has been found to be the most clinically relevant cross-reacting allergenic component, able to induce severe reactions. PR-10, profilin, defensin, chitinase, and gibberellin-regulated proteins are other important cross-reactive allergen molecules. Artemisia pollen can induce allergenic cross-reactions with a wide range of plant-derived foods in China, and spring tree pollens (Betula) are also important. nsLTP found in both pollen and plant-derived food is considered the most significant allergen in food pollen cross-reactivity. Component-resolved diagnosis with potential allergenic proteins is recommended to improve diagnostic accuracy and predict the potential risk of causing allergic symptoms.

综述的目的:植物源性食物是中国最常见的食物过敏致病源之一,与花粉过敏有重要关系。本综述旨在全面概述这种食物-花粉过敏综合征及其分子过敏原诊断,以更好地了解交叉反应的基础:最近的研究结果:食物-花粉交叉反应主要发生在中国北方,蒿属花粉是主要的相关吸入源,其次是树花粉(桦树花粉),草花粉的作用较小。花粉过敏在华南地区相对较少,草花粉过敏比杂草和树花粉过敏更为严重。蔷薇科水果和豆类种子是主要的相关致敏食物。研究发现,非特异性脂质转移蛋白(nsLTP)是临床上最具交叉反应性的过敏原成分,可诱发严重反应。其他重要的交叉反应过敏原分子还包括 PR-10、profilin、defensin、几丁质酶和赤霉素调节蛋白。在中国,青蒿花粉可诱导与多种植物衍生食物的过敏原交叉反应,春树花粉(桦树花粉)也是重要的过敏原。建议使用潜在过敏原蛋白进行成分解析诊断,以提高诊断准确性并预测引起过敏症状的潜在风险。
{"title":"Food-Pollen Cross-Reactivity and its Molecular Diagnosis in China.","authors":"Lan Zhao, Tingting Ma, Xiaoyan Wang, Hongtian Wang, Yi Liu, Shandong Wu, Linglin Fu, Luud Gilissen, Ronald van Ree, Xueyan Wang, Zhongshan Gao","doi":"10.1007/s11882-024-01162-w","DOIUrl":"10.1007/s11882-024-01162-w","url":null,"abstract":"<p><strong>Purpose of review: </strong>Plant-derived foods are one of the most common causative sources of food allergy in China, with a significant relationship to pollinosis. This review aims to provide a comprehensive overview of this food-pollen allergy syndrome and its molecular allergen diagnosis to better understand the cross-reactive basis.</p><p><strong>Recent findings: </strong>Food-pollen cross-reactivity has been mainly reported in Northern China, Artemisia pollen is the major related inhalant source, followed by tree pollen (Betula), while grass pollen plays a minor role. Pollen allergy is relatively low in Southern China, with allergies to grass pollen being more important than weed and tree pollens. Rosaceae fruits and legume seeds stand out as major related allergenic foods. Non-specific lipid transfer protein (nsLTP) has been found to be the most clinically relevant cross-reacting allergenic component, able to induce severe reactions. PR-10, profilin, defensin, chitinase, and gibberellin-regulated proteins are other important cross-reactive allergen molecules. Artemisia pollen can induce allergenic cross-reactions with a wide range of plant-derived foods in China, and spring tree pollens (Betula) are also important. nsLTP found in both pollen and plant-derived food is considered the most significant allergen in food pollen cross-reactivity. Component-resolved diagnosis with potential allergenic proteins is recommended to improve diagnostic accuracy and predict the potential risk of causing allergic symptoms.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":" ","pages":"497-508"},"PeriodicalIF":5.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141556006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neglected but Clinically Relevant Allergens in Korea. 韩国被忽视但与临床相关的过敏原。
IF 5.4 2区 医学 Q1 ALLERGY Pub Date : 2024-09-01 Epub Date: 2024-07-09 DOI: 10.1007/s11882-024-01161-x
Kyoung Yong Jeong, Jung-Won Park

Purpose of review: Allergy diagnostics and immunotherapeutics in Asia heavily rely on imported products from Western countries, raising concerns about the accuracy and efficacy of these products for the management of Asian allergy patients.

Recent findings: Recent advancements in allergen research have led to the identification and characterization of novel allergens from indigenous Korean species. While some allergens share homology with well-known allergens, others lack counterparts in imported allergen extracts. Classifying regional allergens in Asia into three categories based on their cross-reactivity with imported allergens offers valuable insights. Highly cross-reactive allergens, such as oak allergens Que m 1 from Quercus mongolica and Que ac 1 from Q. acutissima, can be effectively substituted with the imported allergens. Allergens with partial cross-reactivity, like the Asian needle ant allergen Pac c 3 (Antigen 5), permit limited diagnostic value by the currently available products. Unique allergens, including the Japanese hop allergen Hum j 6 (pectin methylesterase inhibitor) and the silkworm pupa allergen Bomb m 4 (30 kDa hemolymph lipoprotein) lack alternatives in the available product list. Greater attention is needed, particularly for species listed as ecologically invasive in Western regions. Additionally, allergens from domestic fruits and vegetables causing pollen food allergy syndrome require characterization for the development of improved diagnostics.

综述的目的:亚洲的过敏诊断和免疫疗法在很大程度上依赖于西方国家的进口产品,这引起了人们对这些产品用于治疗亚洲过敏患者的准确性和有效性的担忧:最近的研究结果:过敏原研究的最新进展已导致从韩国本土物种中鉴定出新型过敏原并确定其特征。虽然有些过敏原与众所周知的过敏原具有同源性,但有些过敏原在进口过敏原提取物中却缺乏对应物。根据与进口过敏原的交叉反应性,将亚洲地区的过敏原分为三类,可提供有价值的见解。高度交叉反应的过敏原,如来自Quercus mongolica的橡树过敏原Que m 1和来自Q. acutissima的Que ac 1,可以有效地替代进口过敏原。具有部分交叉反应性的过敏原,如亚洲针蚁过敏原 Pac c 3(抗原 5),目前可用产品的诊断价值有限。独特的过敏原,包括日本酒花过敏原 Hum j 6(果胶甲基酯酶抑制剂)和蚕蛹过敏原 Bomb m 4(30 kDa 血淋巴脂蛋白),在现有产品列表中没有替代品。需要给予更多关注,尤其是被列为西部地区生态入侵物种的物种。此外,导致花粉食物过敏综合症的家用水果和蔬菜过敏原也需要进行特征描述,以便开发出更好的诊断方法。
{"title":"Neglected but Clinically Relevant Allergens in Korea.","authors":"Kyoung Yong Jeong, Jung-Won Park","doi":"10.1007/s11882-024-01161-x","DOIUrl":"10.1007/s11882-024-01161-x","url":null,"abstract":"<p><strong>Purpose of review: </strong>Allergy diagnostics and immunotherapeutics in Asia heavily rely on imported products from Western countries, raising concerns about the accuracy and efficacy of these products for the management of Asian allergy patients.</p><p><strong>Recent findings: </strong>Recent advancements in allergen research have led to the identification and characterization of novel allergens from indigenous Korean species. While some allergens share homology with well-known allergens, others lack counterparts in imported allergen extracts. Classifying regional allergens in Asia into three categories based on their cross-reactivity with imported allergens offers valuable insights. Highly cross-reactive allergens, such as oak allergens Que m 1 from Quercus mongolica and Que ac 1 from Q. acutissima, can be effectively substituted with the imported allergens. Allergens with partial cross-reactivity, like the Asian needle ant allergen Pac c 3 (Antigen 5), permit limited diagnostic value by the currently available products. Unique allergens, including the Japanese hop allergen Hum j 6 (pectin methylesterase inhibitor) and the silkworm pupa allergen Bomb m 4 (30 kDa hemolymph lipoprotein) lack alternatives in the available product list. Greater attention is needed, particularly for species listed as ecologically invasive in Western regions. Additionally, allergens from domestic fruits and vegetables causing pollen food allergy syndrome require characterization for the development of improved diagnostics.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":" ","pages":"519-526"},"PeriodicalIF":5.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141560422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Legume Allergens Pea, Chickpea, Lentil, Lupine and Beyond. 豆类过敏原 豌豆、鹰嘴豆、扁豆、羽扇豆及更多。
IF 5.4 2区 医学 Q1 ALLERGY Pub Date : 2024-09-01 Epub Date: 2024-07-11 DOI: 10.1007/s11882-024-01165-7
Marua Abu Risha, Eva-Maria Rick, Melanie Plum, Uta Jappe

Purpose of the review: In the last decade, an increasing trend towards a supposedly healthier vegan diet could be observed. However, recently, more cases of allergic reactions to plants and plant-based products such as meat-substitution products, which are often prepared with legumes, were reported. Here, we provide the current knowledge on legume allergen sources and the respective single allergens. We answer the question of which legumes beside the well-known food allergen sources peanut and soybean should be considered for diagnostic and therapeutic measures.

Recent findings: These "non-priority" legumes, including beans, pea, lentils, chickpea, lupine, cowpea, pigeon pea, and fenugreek, are potentially new important allergen sources, causing mild-to-severe allergic reactions. Severe reactions have been described particularly for peas and lupine. An interesting aspect is the connection between anaphylactic reactions and exercise (food-dependent exercise-induced anaphylaxis), which has only recently been highlighted for legumes such as soybean, lentils and chickpea. Most allergic reactions derive from IgE cross-reactions to homologous proteins, for example between peanut and lupine, which is of particular importance for peanut-allergic individuals ignorant to these cross-reactions. From our findings we conclude that there is a need for large-scale studies that are geographically distinctive because most studies are case reports, and geographic differences of allergic diseases towards these legumes have already been discovered for well-known "Big 9" allergen sources such as peanut and soybean. Furthermore, the review illustrates the need for a better molecular diagnostic for these emerging non-priority allergen sources to evaluate IgE cross-reactivities to known allergens and identify true allergic reactions.

回顾的目的:在过去十年中,人们越来越倾向于采用所谓更健康的纯素饮食。然而,最近有更多关于对植物和植物性产品(如肉类替代产品,通常使用豆类烹制)过敏的病例报道。在此,我们提供了有关豆类过敏原来源和相应单一过敏原的现有知识。除了众所周知的食物过敏源花生和大豆外,我们还回答了哪些豆科植物应考虑采取诊断和治疗措施的问题:这些 "非重点 "豆科植物,包括豆类、豌豆、扁豆、鹰嘴豆、羽扇豆、豇豆、鸽子豆和葫芦巴,可能是新的重要过敏原来源,会引起轻度到严重的过敏反应。豌豆和羽扇豆的严重反应尤为明显。一个有趣的方面是过敏反应与运动之间的联系(食物依赖性运动诱发过敏性休克),这一点直到最近才在大豆、扁豆和鹰嘴豆等豆科植物中得到强调。大多数过敏反应源于同源蛋白质的 IgE 交叉反应,例如花生和羽扇豆之间的交叉反应,这对于对这些交叉反应一无所知的花生过敏症患者来说尤为重要。根据我们的研究结果,我们得出结论:需要开展具有地域特色的大规模研究,因为大多数研究都是病例报告,而对于花生和大豆等众所周知的 "九大 "过敏源,人们已经发现了这些豆科植物过敏性疾病的地域差异。此外,该综述还说明,需要对这些新出现的非优先过敏原来源进行更好的分子诊断,以评估与已知过敏原的 IgE 交叉反应性,并确定真正的过敏反应。
{"title":"Legume Allergens Pea, Chickpea, Lentil, Lupine and Beyond.","authors":"Marua Abu Risha, Eva-Maria Rick, Melanie Plum, Uta Jappe","doi":"10.1007/s11882-024-01165-7","DOIUrl":"10.1007/s11882-024-01165-7","url":null,"abstract":"<p><strong>Purpose of the review: </strong>In the last decade, an increasing trend towards a supposedly healthier vegan diet could be observed. However, recently, more cases of allergic reactions to plants and plant-based products such as meat-substitution products, which are often prepared with legumes, were reported. Here, we provide the current knowledge on legume allergen sources and the respective single allergens. We answer the question of which legumes beside the well-known food allergen sources peanut and soybean should be considered for diagnostic and therapeutic measures.</p><p><strong>Recent findings: </strong>These \"non-priority\" legumes, including beans, pea, lentils, chickpea, lupine, cowpea, pigeon pea, and fenugreek, are potentially new important allergen sources, causing mild-to-severe allergic reactions. Severe reactions have been described particularly for peas and lupine. An interesting aspect is the connection between anaphylactic reactions and exercise (food-dependent exercise-induced anaphylaxis), which has only recently been highlighted for legumes such as soybean, lentils and chickpea. Most allergic reactions derive from IgE cross-reactions to homologous proteins, for example between peanut and lupine, which is of particular importance for peanut-allergic individuals ignorant to these cross-reactions. From our findings we conclude that there is a need for large-scale studies that are geographically distinctive because most studies are case reports, and geographic differences of allergic diseases towards these legumes have already been discovered for well-known \"Big 9\" allergen sources such as peanut and soybean. Furthermore, the review illustrates the need for a better molecular diagnostic for these emerging non-priority allergen sources to evaluate IgE cross-reactivities to known allergens and identify true allergic reactions.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":" ","pages":"527-548"},"PeriodicalIF":5.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11364600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141581583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New insights into chronic inducible urticaria. 对慢性诱发性荨麻疹的新认识。
IF 5.4 2区 医学 Q1 ALLERGY Pub Date : 2024-08-01 Epub Date: 2024-07-19 DOI: 10.1007/s11882-024-01160-y
Melba Muñoz, Lea Alice Kiefer, Manuel P Pereira, Mojca Bizjak, Marcus Maurer

Purpose of review: Chronic inducible urticaria (CIndU) is a group of long-persisting and challenging to manage diseases, characterized by recurrent wheals and angioedema induced by definite triggers. In this review, we address recent findings on CIndU pathogenesis, diagnosis as well as its treatment, and we discuss novel potential targets that may lead to the development of more effective therapies for CIndU patients.

Recent advances: Meaningful advances in the understanding of its pathogenesis have been reported in the last decades. Novel CIndU-specific patient-reported outcome measures enable a closer and better evaluation of patients. CIndU is a hard-to-treat disease that highly impairs quality of life (QoL) of affected patients. Provocation tests allow to diagnose CIndU subtypes. The only licensed and recommended treatment for CIndU are second generation non-sedating H1-antihistamines, which lack efficacy in many cases. Omalizumab off-label use has been assessed in all types of CIndU with overall good outcomes. Promising emerging therapies currently assessed in chronic spontaneous urticaria are paving the path for novel treatments for CIndU.

综述的目的:慢性诱发性荨麻疹(CIndU)是一类长期存在且难以控制的疾病,其特点是由明确的诱发因素诱发反复发作的喘息和血管性水肿。在这篇综述中,我们探讨了有关诱发性荨麻疹发病机制、诊断和治疗的最新发现,并讨论了可能为诱发性荨麻疹患者开发出更有效疗法的潜在新靶点:最近的进展:在过去几十年中,人们对CIndU发病机制的认识取得了重大进展。新的CIndU特异性患者报告结果测量方法使我们能够更仔细、更好地评估患者。CIndU是一种难以治疗的疾病,严重影响患者的生活质量(QoL)。激发试验可以诊断 CIndU 亚型。CIndU的唯一许可和推荐治疗药物是第二代非镇静型H1-抗组胺药,但在许多病例中缺乏疗效。奥马珠单抗已被评估用于所有类型的CIndU,总体疗效良好。目前在慢性自发性荨麻疹中评估的新兴疗法前景广阔,为CIndU的新型疗法铺平了道路。
{"title":"New insights into chronic inducible urticaria.","authors":"Melba Muñoz, Lea Alice Kiefer, Manuel P Pereira, Mojca Bizjak, Marcus Maurer","doi":"10.1007/s11882-024-01160-y","DOIUrl":"10.1007/s11882-024-01160-y","url":null,"abstract":"<p><strong>Purpose of review: </strong>Chronic inducible urticaria (CIndU) is a group of long-persisting and challenging to manage diseases, characterized by recurrent wheals and angioedema induced by definite triggers. In this review, we address recent findings on CIndU pathogenesis, diagnosis as well as its treatment, and we discuss novel potential targets that may lead to the development of more effective therapies for CIndU patients.</p><p><strong>Recent advances: </strong>Meaningful advances in the understanding of its pathogenesis have been reported in the last decades. Novel CIndU-specific patient-reported outcome measures enable a closer and better evaluation of patients. CIndU is a hard-to-treat disease that highly impairs quality of life (QoL) of affected patients. Provocation tests allow to diagnose CIndU subtypes. The only licensed and recommended treatment for CIndU are second generation non-sedating H1-antihistamines, which lack efficacy in many cases. Omalizumab off-label use has been assessed in all types of CIndU with overall good outcomes. Promising emerging therapies currently assessed in chronic spontaneous urticaria are paving the path for novel treatments for CIndU.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":" ","pages":"457-469"},"PeriodicalIF":5.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11297124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141725130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Managing Symptoms of Systemic Sclerosis for the Allergist-Immunologist. 过敏反应学家--免疫学家系统性硬化症症状管理》(Managing Symptoms of Systemic Sclerosis for the Allergist-Immunologist.
IF 5.4 2区 医学 Q1 ALLERGY Pub Date : 2024-08-01 Epub Date: 2024-06-21 DOI: 10.1007/s11882-024-01155-9
Mehreen Elahee, Robyn T Domsic

Purpose of review: Systemic sclerosis (SSc) is a chronic, multisystem, autoimmune disease characterized by fibrosis, vasculopathy and immune system dysregulation. We provide a comprehensive review of features of systemic sclerosis that can potentially present to the allergist.

Recent findings: A thorough understanding of the management options is crucial for clinicians involved in the care of patients with SSc to optimize clinical outcomes. Management of systemic sclerosis has drastically changed in the last decade and continues to evolve. This review provides an overview of management strategies for the various symptoms including skin, upper and lower airway, gastrointestinal and vascular manifestations. Institution of treatment early in the disease, including referral to rheumatology or specialized scleroderma centers, can help to both prevent and manage disease complications, and improve patient quality-of-life. While the landscape of systemic sclerosis management has evolved, we continue to recognize that there is still a need for better biomarkers and targeted therapies.

综述的目的:系统性硬化症(SSc)是一种慢性、多系统、自身免疫性疾病,以纤维化、血管病变和免疫系统失调为特征。我们全面综述了过敏学家可能会发现的系统性硬化症的特征:透彻了解治疗方案对于参与治疗系统性硬化症患者的临床医生优化临床疗效至关重要。在过去十年中,系统性硬化症的治疗方法发生了巨大变化,并且仍在不断发展。本综述概述了针对各种症状(包括皮肤、上下气道、胃肠道和血管表现)的治疗策略。在疾病早期进行治疗,包括转诊到风湿病学或专业硬皮病中心,有助于预防和控制疾病并发症,改善患者的生活质量。虽然系统性硬皮病的治疗方式已经发生了变化,但我们仍然认识到,仍然需要更好的生物标志物和靶向疗法。
{"title":"Managing Symptoms of Systemic Sclerosis for the Allergist-Immunologist.","authors":"Mehreen Elahee, Robyn T Domsic","doi":"10.1007/s11882-024-01155-9","DOIUrl":"10.1007/s11882-024-01155-9","url":null,"abstract":"<p><strong>Purpose of review: </strong>Systemic sclerosis (SSc) is a chronic, multisystem, autoimmune disease characterized by fibrosis, vasculopathy and immune system dysregulation. We provide a comprehensive review of features of systemic sclerosis that can potentially present to the allergist.</p><p><strong>Recent findings: </strong>A thorough understanding of the management options is crucial for clinicians involved in the care of patients with SSc to optimize clinical outcomes. Management of systemic sclerosis has drastically changed in the last decade and continues to evolve. This review provides an overview of management strategies for the various symptoms including skin, upper and lower airway, gastrointestinal and vascular manifestations. Institution of treatment early in the disease, including referral to rheumatology or specialized scleroderma centers, can help to both prevent and manage disease complications, and improve patient quality-of-life. While the landscape of systemic sclerosis management has evolved, we continue to recognize that there is still a need for better biomarkers and targeted therapies.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":" ","pages":"433-441"},"PeriodicalIF":5.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141433431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of the Microbiome in Allergy, Asthma, and Occupational Lung Disease. 微生物组在过敏、哮喘和职业性肺病中的作用。
IF 5.4 2区 医学 Q1 ALLERGY Pub Date : 2024-08-01 Epub Date: 2024-06-21 DOI: 10.1007/s11882-024-01156-8
Ashley Peer, Derrick R Samuelson

Purpose of review: The human commensal microbiota is now widely accepted as a key regulator of human health and disease. The composition of the mucosal associated microbiota has been shown to play a critical role in the lung health. The role of the mucosal microbiota in the development and severity of allergy, asthma, and occupational lung disease is only beginning to take shape. However, advances in our understanding of these links have tremendous potential to led to new clinical interventions to reduce allergy, asthma, and occupational lung disease morbidity.

Recent findings: We review recent work describing the relationship and role of the commensal microbiota in the development of allergy, asthma, and occupational lung disease. Our review primarily focuses on occupational exposures and the effects of the microbiome, both in composition and function. Data generated from these studies may lead to the development of interventions targeted at establishing and maintaining a healthy microbiota. We also highlight the role of environmental exposures and the effects on the commensal microbial community and their potential association with occupational lung disease. This review explores the current research describing the role of the human microbiome in the regulation of pulmonary health and disease, with a specific focus on the role of the mucosal microbiota in the development of allergy, asthma, and occupational lung disease.

综述的目的:人类共生微生物群现已被广泛认为是人类健康和疾病的关键调节因子。粘膜相关微生物群的组成已被证明对肺部健康起着至关重要的作用。粘膜微生物群在过敏、哮喘和职业性肺病的发生和严重程度中的作用才刚刚开始形成。然而,我们对这些联系的认识取得的进展具有巨大的潜力,可促成新的临床干预措施,降低过敏、哮喘和职业性肺病的发病率:我们回顾了近期有关共生微生物群在过敏、哮喘和职业性肺病发病中的关系和作用的研究。我们的综述主要侧重于职业暴露和微生物组的影响,包括微生物组的组成和功能。这些研究产生的数据可能有助于制定干预措施,以建立和维持健康的微生物群。我们还强调了环境暴露的作用、对共生微生物群落的影响及其与职业性肺病的潜在关联。本综述探讨了目前关于人类微生物群在肺部健康和疾病调控中的作用的研究,特别关注粘膜微生物群在过敏、哮喘和职业性肺病发病中的作用。
{"title":"The Role of the Microbiome in Allergy, Asthma, and Occupational Lung Disease.","authors":"Ashley Peer, Derrick R Samuelson","doi":"10.1007/s11882-024-01156-8","DOIUrl":"10.1007/s11882-024-01156-8","url":null,"abstract":"<p><strong>Purpose of review: </strong>The human commensal microbiota is now widely accepted as a key regulator of human health and disease. The composition of the mucosal associated microbiota has been shown to play a critical role in the lung health. The role of the mucosal microbiota in the development and severity of allergy, asthma, and occupational lung disease is only beginning to take shape. However, advances in our understanding of these links have tremendous potential to led to new clinical interventions to reduce allergy, asthma, and occupational lung disease morbidity.</p><p><strong>Recent findings: </strong>We review recent work describing the relationship and role of the commensal microbiota in the development of allergy, asthma, and occupational lung disease. Our review primarily focuses on occupational exposures and the effects of the microbiome, both in composition and function. Data generated from these studies may lead to the development of interventions targeted at establishing and maintaining a healthy microbiota. We also highlight the role of environmental exposures and the effects on the commensal microbial community and their potential association with occupational lung disease. This review explores the current research describing the role of the human microbiome in the regulation of pulmonary health and disease, with a specific focus on the role of the mucosal microbiota in the development of allergy, asthma, and occupational lung disease.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":" ","pages":"415-423"},"PeriodicalIF":5.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11297072/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141433432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Allergy and Asthma Reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1